Navigation Links
TPI Provides Further Updates on its GMOL Flagship Product
Date:7/6/2012

CHENGDU, China, July 6, 2012 /PRNewswire-Asia/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI, or the "Company"), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) today provided further updates on the business development of TPI's flagship product: Gingko Mihuan Oral Liquid or GMOL (H20013079), a prescription medicine that is used by physicians for cardiovascular diseases such as stroke, coronary heart diseases, angina, etc. The additional information regarding GMOL can also be accessed at www.sfda.gov.cn, (Chinese version) or http://baike.baidu.com/view/3029034.htm. GMOL was recently awarded Essential Drug List (EDL) status in the City of Chongqing. Chongqing, located in southwest China, with a population over 30 million and its status as the municipality directly under the jurisdiction of the PRC Government along with other major cities with the same status, Beijing, Tianjin and Shanghai which are located in the east coastal area are regarded one of the most attractive markets in pharmaceutical sales in China.

In April, TPI has announced the inclusion of GMOL as a provincial supplementary Essential Drug Listed (EDL) product in both Henan and Shandong provinces (with combined population of approximately 200 million) which granted GMOL a full insurance coverage (100% government reimbursement) for patients. GMOL contributes approximately 50% of TPI's core product portfolio that consists of GMOL, Apu Shuangxin Granules (Apu), Azithromycin Tablets (Azi), Xuelian Chongcao (XLCC) and Qingre Jiedu Oral Liquid (QR) and approximately 30% of TPI's total revenue.  

Under the ongoing healthcare reform policy that favors the sale of products that are listed in the EDL of China, the national and provincial EDL listing could substantiate the market development of these products.

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the national essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. For more information about TPI, please visit:  http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email ir@tpi.asia

Tel:     +86-28-8551-6696 (Chengdu, China)           +86-134-3655-0011 (China)

Address: Tianyin Pharmaceutical 23rd Floor, Unionsun Yangkuo Plaza       No. 2, Block 3, South Renmin Road Chengdu, 610041 China


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
2. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
3. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
4. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
5. Elevate Provides Remote Access to Personal Health Records Using MyMedicalRecords.com
6. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
7. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
8. Concord Medical Announces its Successful Closing of the Acquisition of 52% Ownership in Changan Hospital and Provides Guidance for Financial Results of the Second Quarter of 2012
9. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
10. OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers
11. Elekta and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital Sign Strategic Alliance to Further Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  CVS Health (NYSE: ... living in Santa Clara County, CA ... on the Santa Clara University campus. CVS Pharmacy stores ... protect patients against the disease. Students at Santa Clara ... get vaccinated. In addition, anyone who has had close ...
(Date:2/10/2016)... LOS ANGELES , Feb. 10, 2016  Oxis ... blood cancer drug, OXS-1550, was described as a "clinical ... with the drug went into complete cancer remission. ... the University of Minnesota Masonic Cancer Center. ... the University of Minnesota Masonic Cancer Center. ...
(Date:2/10/2016)... Feb. 10, 2016  LexisNexis® Risk Solutions, a ... announced the launch of LexisNexis Provider Performance ... helps improve and optimize the quality and efficiency ... using severity-adjusted scores. By measuring provider performance through ... to deliver better outcomes, improve the patient experience ...
Breaking Medicine Technology:
(Date:2/10/2016)... TX (PRWEB) , ... February 10, 2016 , ... ... commencement of a master charity program created to assist the local community. Pledging ... with community leaders and nonprofit organizations in the area. Their goal is to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Peyman Ghasri, ... now offering a variety of comprehensive procedures for facial enhancement. The treatments now ... restoration, lip enhancement and nasal reshaping. , As a result, patients can ...
(Date:2/10/2016)... St. Louis, Missouri (PRWEB) , ... February 10, ... ... 11-14, 2016, in San Diego, will bring together more than 200 of the ... in healthcare for the future. , “The true benefit of the Forum is ...
(Date:2/10/2016)... ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology ... quarter and full year ended December 31, 2015 on Monday, February 29, 2016 after ... the investment community following the release at 4:30 PM ET. Investors interested in participating ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... to effectively measure change in their patients. Research shows that the Goal Attainment ... To help therapists overcome this challenge and learn more about the Goal Attainment ...
Breaking Medicine News(10 mins):